AI-generated from publicly available materials.The integration of artificial intelligence (AI) in drug discovery poses significant challenges regarding the reliability of AI-generated evidence, particularly concerning regulatory compliance and legal risks.
AI models utilized in drug development are fundamentally probabilistic, which means they can produce outputs that may seem plausible yet be incorrect. This issue is exacerbated by three primary flaws: reliance on incomplete datasets, the opaque nature of AI reasoning, and sensitivity to minor input changes, which can compromise the reproducibility of results. These factors raise concerns about the integrity of regulatory submissions and the potential for legal liabilities, especially when AI-generated data is submitted without independent verification.
Another critical risk arises from adversarial manipulation of training data, which can lead to skewed predictions and misrepresentations in regulatory contexts. The FDA and EU are increasingly expected to provide guidance on the use of AI in drug development, emphasizing the necessity for human oversight and validation to mitigate these risks. Companies are urged to adopt robust data governance practices and maintain transparency in AI processes to align with evolving regulatory frameworks.
This scenario underscores the importance of rigorous validation and oversight in AI applications within life sciences. As regulatory bodies refine their expectations, organizations must adapt to ensure compliance and safeguard against potential legal repercussions stemming from AI-generated evidence.